39.59
price up icon0.51%   0.20
after-market After Hours: 39.54 -0.05 -0.13%
loading
Moderna Inc stock is traded at $39.59, with a volume of 4.94M. It is up +0.51% in the last 24 hours and down -3.70% over the past month. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$39.39
Open:
$39.19
24h Volume:
4.94M
Relative Volume:
0.68
Market Cap:
$15.23B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-4.2342
EPS:
-9.35
Net Cash Flow:
$-3.96B
1W Performance:
-5.38%
1M Performance:
-3.70%
6M Performance:
-70.32%
1Y Performance:
-58.28%
1-Day Range:
Value
$38.52
$40.34
1-Week Range:
Value
$37.44
$43.17
52-Week Range:
Value
$35.80
$170.47

Moderna Inc Stock (MRNA) Company Profile

Name
Name
Moderna Inc
Name
Phone
(617) 714-6500
Name
Address
325 BINNEY STREET, CAMBRIDGE
Name
Employee
5,600
Name
Twitter
@moderna_tx
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MRNA's Discussions on Twitter

Compare MRNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MRNA
Moderna Inc
39.59 15.23B 5.06B -2.22B -3.96B -5.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
405.27 104.37B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
715.13 78.59B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
628.32 37.57B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.26 31.25B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.51 27.21B 3.30B -501.07M 1.03B -2.1146

Moderna Inc Stock (MRNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-18-24 Downgrade Argus Buy → Hold
Dec-10-24 Resumed BofA Securities Underperform
Nov-19-24 Initiated Berenberg Hold
Nov-18-24 Upgrade HSBC Securities Hold → Buy
Nov-15-24 Initiated Wolfe Research Underperform
Oct-17-24 Initiated Bernstein Mkt Perform
Sep-13-24 Downgrade JP Morgan Neutral → Underweight
Sep-13-24 Downgrade Jefferies Buy → Hold
Sep-13-24 Downgrade Oppenheimer Outperform → Perform
Aug-28-24 Upgrade HSBC Securities Reduce → Hold
Aug-07-24 Upgrade Deutsche Bank Sell → Hold
Aug-05-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-26-24 Downgrade HSBC Securities Hold → Reduce
Jan-02-24 Upgrade Oppenheimer Perform → Outperform
Nov-29-23 Initiated Canaccord Genuity Hold
Nov-03-23 Upgrade HSBC Securities Reduce → Hold
Nov-02-23 Downgrade Deutsche Bank Hold → Sell
Aug-04-23 Downgrade TD Cowen Outperform → Market Perform
Aug-03-23 Downgrade Deutsche Bank Buy → Hold
Jul-24-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Reduce
Jun-26-23 Upgrade UBS Neutral → Buy
Apr-26-23 Initiated Guggenheim Neutral
Mar-13-23 Upgrade TD Cowen Market Perform → Outperform
Mar-02-23 Initiated RBC Capital Mkts Outperform
Feb-24-23 Downgrade SVB Securities Market Perform → Underperform
Dec-19-22 Upgrade Jefferies Hold → Buy
Dec-14-22 Downgrade Chardan Capital Markets Buy → Neutral
Oct-21-22 Upgrade SVB Leerink Underperform → Mkt Perform
Sep-08-22 Upgrade Deutsche Bank Hold → Buy
Feb-01-22 Upgrade Redburn Sell → Neutral
Jan-26-22 Upgrade Deutsche Bank Sell → Hold
Jan-21-22 Upgrade BofA Securities Underperform → Neutral
Jan-21-22 Initiated UBS Neutral
Dec-07-21 Initiated Cowen Market Perform
Nov-09-21 Initiated Wolfe Research Outperform
Oct-22-21 Initiated Deutsche Bank Sell
Oct-15-21 Upgrade Piper Sandler Neutral → Overweight
Aug-06-21 Downgrade Oppenheimer Outperform → Perform
Aug-06-21 Downgrade Piper Sandler Overweight → Neutral
Jul-15-21 Reiterated Jefferies Hold
Feb-01-21 Downgrade BofA Securities Neutral → Underperform
Dec-16-20 Downgrade Jefferies Buy → Hold
Dec-16-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-20 Downgrade Needham Buy → Hold
Nov-23-20 Initiated Wells Fargo Equal Weight
Nov-17-20 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-08-20 Downgrade SVB Leerink Mkt Perform → Underperform
Jul-23-20 Initiated SVB Leerink Mkt Perform
Jul-20-20 Downgrade JP Morgan Overweight → Neutral
Jul-13-20 Initiated Jefferies Buy
Jun-30-20 Initiated Argus Buy
Jun-08-20 Initiated Barclays Overweight
Apr-30-20 Initiated BMO Capital Markets Outperform
Mar-05-20 Downgrade BofA/Merrill Buy → Neutral
Dec-03-19 Resumed BofA/Merrill Buy
Oct-25-19 Initiated ROTH Capital Buy
Apr-05-19 Initiated Chardan Capital Markets Buy
View All

Moderna Inc Stock (MRNA) Latest News

pulisher
04:32 AM

Moderna Inc. stock rises Monday, still underperforms market - MarketWatch

04:32 AM
pulisher
08:03 AM

Moderna Stock Down 39% in Three Months: Buy the Dip or Wait? - Nasdaq

08:03 AM
pulisher
Dec 22, 2024

While Moderna (NASDAQ:MRNA) shareholders have made 102% in 5 years, increasing losses might now be front of mind as stock sheds 5.8% this week - Simply Wall St

Dec 22, 2024
pulisher
Dec 20, 2024

Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch

Dec 20, 2024
pulisher
Dec 20, 2024

California’s bird flu emergency spotlights need for advanced therapeutics - Proactive Investors UK

Dec 20, 2024
pulisher
Dec 20, 2024

Is Moderna Stock a Buy? - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

3 Stocks That Could Turn $1,000 into $5,000 by 2030 - The Motley Fool

Dec 20, 2024
pulisher
Dec 19, 2024

Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch

Dec 19, 2024
pulisher
Dec 19, 2024

Moderna, Inc. (MRNA) Faces Criticism from Cramer Amid High R&D Spending and Revenue Struggles - Insider Monkey

Dec 19, 2024
pulisher
Dec 19, 2024

Personalis Secures $50M from Merck, Extends Collaboration with Moderna - HIT Consultant

Dec 19, 2024
pulisher
Dec 19, 2024

RNA Therapy Clinical Trials Market to Reach USD 4.16 Billion to 2034 - BioSpace

Dec 19, 2024
pulisher
Dec 19, 2024

Merck Buys $50 Million of Personalis Stock - Marketscreener.com

Dec 19, 2024
pulisher
Dec 19, 2024

Personalis Lands $50M Merck Investment, Extends Key Moderna Partnership for Cancer Therapy Platform - StockTitan

Dec 19, 2024
pulisher
Dec 19, 2024

Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Stifel Financial Corp - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Moderna Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Dec 18, 2024
pulisher
Dec 18, 2024

Moderna lowered to hold at Argus amid lower COVID vaccine sales, competitive RSV market - MSN

Dec 18, 2024
pulisher
Dec 18, 2024

Argus downgrades Moderna to hold on weak near-term outlook - MSN

Dec 18, 2024
pulisher
Dec 18, 2024

This Feels Like the Post-Pandemic Rally. 3 Stocks to Buy If It Is - 24/7 Wall St.

Dec 18, 2024
pulisher
Dec 18, 2024

Moderna shares downgraded to hold from buy by Argus on revenue decline - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Argus Downgrades Moderna (NASDAQ:MRNA) to Hold - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Hedge Funds Think That Moderna, Inc. (MRNA) Will Bounce Back Soon - Insider Monkey

Dec 18, 2024
pulisher
Dec 18, 2024

Moderna: Cutting Costs Might Not Be Enough (NASDAQ:MRNA) - Seeking Alpha

Dec 18, 2024
pulisher
Dec 17, 2024

Moderna Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Dec 17, 2024
pulisher
Dec 17, 2024

Moderna Halts mRNA RSV Vaccine Trial for Children After Five Infants were Hospitalized - WCBM

Dec 17, 2024
pulisher
Dec 17, 2024

Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop - BioSpace

Dec 17, 2024
pulisher
Dec 16, 2024

What's Going On With Moderna Stock On Monday? - Yahoo Finance

Dec 16, 2024
pulisher
Dec 16, 2024

Is Moderna Stock Underperforming the Dow? - Nasdaq

Dec 16, 2024
pulisher
Dec 16, 2024

Moderna remains the most shorted among S&P 500 healthcare stocks in November - MSN

Dec 16, 2024
pulisher
Dec 16, 2024

What's Going On With Super Micro Computer Shares Monday? - Benzinga

Dec 16, 2024
pulisher
Dec 16, 2024

Some Of This Year’s Big Losers Look Good To Me - Forbes

Dec 16, 2024
pulisher
Dec 16, 2024

Moderna Continues To Slide YTD with Stock (MRNA) Down 62% - AskTraders

Dec 16, 2024
pulisher
Dec 16, 2024

Is Moderna Stock Underperforming The Dow? - Barchart

Dec 16, 2024
pulisher
Dec 16, 2024

Five things: Editas cuts, CVS shares, Moderna's name and the best birthday gift ever - The Business Journals

Dec 16, 2024
pulisher
Dec 16, 2024

Adult Vaccines Market Generated Opportunities, Future Scope - openPR

Dec 16, 2024
pulisher
Dec 15, 2024

MicroStrategy, Palantir added to Nasdaq 100, with Moderna facing an exit - The Star Online

Dec 15, 2024
pulisher
Dec 15, 2024

Cambridge drugmaker wins city approval to put its sign above the treeline - The Business Journals

Dec 15, 2024
pulisher
Dec 15, 2024

Quantinno Capital Management LP Cuts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Dec 15, 2024
pulisher
Dec 14, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming DeadlinesMRNA - Victoria Advocate

Dec 14, 2024
pulisher
Dec 14, 2024

Toronto Dominion Bank Raises Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Dec 14, 2024
pulisher
Dec 14, 2024

Saylor’s MicroStrategy Scores Again With Nasdaq 100 Addition - Yahoo Finance

Dec 14, 2024
pulisher
Dec 14, 2024

MicroStrategy, Palantir, Axon Added To Nasdaq 100: Super Micro Computer, Moderna, Illumina Exit The Index - Benzinga

Dec 14, 2024
pulisher
Dec 13, 2024

MicroStrategy, Palantir Added to Nasdaq 100, Moderna Removed - Bloomberg

Dec 13, 2024
pulisher
Dec 13, 2024

Palantir, MicroStrategy Likely To Join Nasdaq 100; Will Moderna, Super Micro Get The Axe? - MSN

Dec 13, 2024
pulisher
Dec 13, 2024

Moderna | History, Innovation, Challenges, & Facts - Britannica

Dec 13, 2024
pulisher
Dec 13, 2024

‘Safety signal’ in Moderna’s RSV vaccine studies halts trials of other vaccines for childhood killer - Science

Dec 13, 2024
pulisher
Dec 13, 2024

FDA panel seeks more data on RSV vaccine safety in infants - BioPharma Dive

Dec 13, 2024
pulisher
Dec 13, 2024

Moderna's SWOT analysis: stock faces transition as covid vaccine demand wanes - Investing.com

Dec 13, 2024
pulisher
Dec 13, 2024

Is Moderna Stock A Sell In December 2024 With Deep Losses Projected For The Fourth Quarter? - Yahoo! Voices

Dec 13, 2024
pulisher
Dec 13, 2024

FDA Committee Calls For More Research After Moderna’s RSV Vaccine Safety Issues - BioSpace

Dec 13, 2024
pulisher
Dec 13, 2024

Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Geode Capital Management LLC - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

The specter of RFK Jr. has investors fretting about a onetime vaccine wunderkind - Yahoo Canada Finance

Dec 13, 2024

Moderna Inc Stock (MRNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$363.65
price up icon 1.13%
$18.67
price up icon 4.48%
$69.84
price up icon 1.45%
$177.70
price up icon 0.68%
$113.51
price up icon 0.38%
Cap:     |  Volume (24h):